Avita Medical Announces 4th Annual Skin Regeneration Symposium

NORTHRIDGE, CA, PERTH, AUSTRALIA and CAMBRIDGE, UNITED KINGDOM--(Marketwired - April 05, 2016) - Avita Medical Ltd, (ASX: AVH) (OTCQX: AVMXY), a company specialising in treatments for wounds and skin defects, today announced that some of the latest research in its field of regenerative medicine will be unveiled at a meeting being held at the University of Cambridge next week.

About 140 experts from around the world are registered to attend The 4th Annual Skin Regeneration Symposium (SRS), which will explore the latest advancements in skin repair, regeneration and restoration and the impact this has on patients. The capacity audience at SRS will see keynote presentations delivered by international experts from the fields of burns, trauma, chronic wounds and aesthetics during the two-day session at the University of Cambridge's Moller Centre, April 12-13.

The educational event, hosted by Avita, provides a forum to showcase research and present robust clinical evidence of Avita's pioneering ReCell® technology, supporting Avita's commercialization drive, by providing the data required by medical professionals and regulatory authorities, as well as drawing from Avita's clinical bibliography of more than 60 abstracts and peer-reviewed publications. In recent months, the Company has published positive data from randomized trials in the areas of pigmentation and venous leg ulcers, while an FDA-approval trial in burns has just completed enrollment.

"Our simple intention with the Skin Regeneration Symposium is to get all the leading researchers we are connected with together, to enjoy a rich and varied exposition of the many strands of clinical and scientific work in which we are engaged," said Avita CEO Adam Kelliher. "Of course, the most important interactions typically happen outside of the presentation, where we should see good cross-fertilisation of ideas, which will inevitably trigger more use of our products."

The event will be opened by Professor Fiona Wood, Director of the Burns Service of Western Australia and innovator behind Avita's regenerative medicine approach, with eight speakers scheduled to present at the first burns-focused session, entitled 'Repair.' Dr Hunghui Liu, of the Burns Service of Taiwan, will speak about how ReCell® was used to treat approximately 60 victims of last summer's Waterpark disaster, near Taipei. Other presentations will look at skin regeneration techniques following burn injuries.

The second session, titled 'Restart,' will cover chronic wounds and include presentations from six researchers. Mr Paul Hayes of Addenbrookes Hospital will give greater detail on the results of Avita's recent randomised trial on Venous Leg Ulcers, in which ReGenerCell™ showed significant results in closing these chronic wounds. Treatment of diabetic foot ulcers will also be an area of focus.

The third session -- 'Restore' -- will emphasise how ReCell™ may be used in the fields of plastics, aesthetics and maxilofacial procedures. Further speakers will talk on a variety of topics in the reconstructive field.

Dr Nik Georgopoulos of the Huddersfield Skin Integrity Institute will deliver a scientific keynote address exploring the underlying mechanisms of the Regenerative Epithelial Suspension (RES) created by Avita's range of products, helping to relate cell biology and clinical observations.

ABOUT AVITA MEDICAL LIMITED

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary collection and application technology provides innovative treatment solutions derived from a patient's own skin. The Company's regenerative product portfolio includes ReCell® for burns & plastic reconstructive procedures, ReGenerCell® for chronic wounds and ReNovaCell® of restoration of pigmentation and cosmesis. ReCell®, ReGenerCell® and ReNovaCell® are patented, CE-marked for Europe. ReCell® is TGA-registered in Australia, and CFDA-cleared in China. In the United States, ReCell® is an investigational device limited by federal law to investigational use, and a pivotal U.S. trial is well underway aimed at securing FDA approval.

To learn more, visit www.avitamedical.com.

AVITA'S REGENERATIVE TECHNOLOGY AND RES™

Avita Medical's unique proprietary technology enables a clinician to rapidly create, at the point of care in approximately 30 minutes, Regenerative Epithelial Suspension (RES™) using a small sample of the patient's skin. RES™ is an autologous suspension comprising the cells and wound healing factors necessary to regenerate natural, healthy skin. RES™ has a broad range of applications and can be used to restart healing in unresponsive wounds, to repair burns using less donor skin yet with improved functional and aesthetic outcomes, and to restore pigmentation and improve cosmesis of damaged skin.

NOTE: Media wishing to attend the 4th Annual Skin Regeneration Symposium should apply via avitamedical@instinctif.com